No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Avalyn Pharma Inc. Common Stock (AVLN) stock was $27.03 as of Oct 5, 2026, 4:00 PM EDT, down 3.91% from the previous close.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase.
Biotechnology · Boston, MA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.98
vs Estimate
$-0.56
Revenue
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AVLN | $1.20B | $27.03 | -3.91% | N/A | N/A | N/A | N/A |
| 2CRON | $1.21B | $3.25 | +0.78% | +25.83% | -9.92% | +13.62% | vs AVLN |
| 3GDRX | $1.16B | $3.36 | +2.44% | -25.72% | -39.98% | N/A | vs AVLN |
| 4DMRA | $1.24B | $20.22 | -2.08% | +429.27% | -25.05% | N/A | vs AVLN |
| 5HROW | $1.14B | $30.58 | +0.33% | -32.56% | +27.66% | +23.49% | vs AVLN |
| 6BCAX | $1.14B | $17.29 | -1.93% | -4.12% | N/A | N/A | vs AVLN |
forward FY estimate
N/A
vs Estimate
$0.00
Consensus Rating
Based on 5 analysts
Average Price Target
$61.80
+128.6% upside
Low
$52.00
Current
$27.03
High
$80.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.71 | $-0.71 | $-0.71 | 1 |
| Quarter ending Dec 2026 | $-0.83 | $-0.83 | $-0.83 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.28 | $-3.28 | $-3.28 | 2 |
| FY 2027 | $-2.96 | $-2.96 | $-2.96 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $0.00 |
| $0.00 |
| $0.00 |
| 0 |
